sameAs
Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study)Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial.Percutaneous coronary intervention in the Occluded Artery Trial: procedural success, hazard, and outcomes over 5 years.Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology.[Guidelines on the management of stable angina pectoris. Executive summary].Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial.Use of multidetector computed tomography for the assessment of acute chest pain: a consensus statement of the North American Society of Cardiac Imaging and the European Society of Cardiac Radiology.Evaluation of safety and efficacy of NexGen - an ultrathin strut and hybrid cell design cobalt-chromium bare metal stent implanted in a real life patient population - the Polish NexGen Registry.Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial.New treatment possibilities for patients with advanced coronary artery disease and critical limb ischemia - a feasibility study.First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial.Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model.Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS all-comers trial.Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.Cardiomyocyte differentiation of bone marrow-derived Oct-4+CXCR4+SSEA-1+ very small embryonic-like stem cells.Stenting and Adjunctive Delivery of Paclitaxel Via Balloon Coating Versus Durable Polymeric Matrix for De Novo Coronary Lesions: Clinical and Angiographic Results from the Prospective Randomized Trial.Left Main Stenting in Comparison With Surgical Revascularization: 10-Year Outcomes of the (Left Main Coronary Artery Stenting) LE MANS Trial.Dose-dependent vascular response following delivery of sirolimus via fast releasing, biodegradable polymer stent matrix: an experimental study in the porcine coronary model of restenosis.A Nuclear Magnetic Resonance Spectroscopy as a Method for Evaluation of In Vivo Poly-l-Lactide Biodegradation Kinetics From Stent-Polymer Matrices: An Experimental Study Utilizing Porcine Model of In-Stent Restenosis.Eptifibatide infusion versus placebo in high risk patients with non-ST segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial.Mobilization of bone marrow-derived Oct-4+ SSEA-4+ very small embryonic-like stem cells in patients with acute myocardial infarction.Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the EarComparison of zotarolimus-eluting and everolimus-eluting coronary stents.The impact of body mass index on the one year outcomes of patients treated by percutaneous coronary intervention with Biolimus- and Sirolimus-eluting stents (from the LEADERS Trial).Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy.Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy.The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).Early and long-term results of unprotected left main coronary artery stenting: the LE MANS (Left Main Coronary Artery Stenting) registry.Percutaneous versus surgical revascularization for multivessel coronary artery disease: a single center 10 year follow-up of SOS trial patients.Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the 'All-Comers' LEADERS trial.Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial.[Heart failure due to chronic hypoparathyroidism in patient with acute coronary syndrome].Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine.Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 months after elective stenting.Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry.Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry.Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: a prospective multicenter registry.The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer.[Acute myocardial infarction with simultaneous occlusions of two coronary arteries in a 44 year-old man].
P50
Q28174849-886F7EB3-F489-4BBB-8F8A-B11D03C0AF77Q33642414-E1B33914-CF16-4D96-BB23-DDB184D3C959Q33646291-FAD710FD-9332-4282-8391-E8AEC0A7E684Q33996248-6182CB02-3A9C-49C3-A4A9-A0F3E3D54690Q34573219-C5A55AE9-06BA-471A-B182-AD2EB49A1C01Q34819606-743379A7-ACB3-42AB-B23B-66DBB66B9862Q35831446-D3B13CD9-0854-410B-90E7-7AC10065AE68Q36840724-7AB02FDE-2944-45CC-ACF3-DE428938ACC0Q37232408-DEB311B1-C2AD-42DE-B796-2F967F9CA612Q37445492-9895AED7-1880-4CD3-8533-06FD7B7D8005Q37463838-2CDCC20A-8294-4A4B-874B-86BD028C8C04Q38398602-38578B30-2106-4B46-999C-B5469A5445A6Q39099311-8F2F3500-0CB8-4A14-8882-4BA21C9FB028Q39353623-74337043-13CE-4867-AFBC-E353C4843A5FQ39492381-6B12B626-E651-4F5D-93BB-9CAFF6A4E2B1Q39685816-889AC2CB-2147-40BB-BD15-0531FFE3B04EQ40680123-47842045-EC74-4B8A-A075-552B95DBE81AQ40901276-E02A03C2-1B3E-4F7A-9824-CBEAC6CA61B3Q40927858-EB7DCC8E-0EE1-4E98-A8B3-FD63EC965194Q40972220-94A09A42-EA79-441E-9E17-3760B3A5D0A4Q40974275-F26E840F-A32B-48FD-8C04-9973984F8A0FQ41189527-9D58E628-820D-4899-A3BE-85AB4AECD8ADQ42641710-B329CA28-751E-423D-BF31-A59DA5E8BF35Q43016712-441843AB-A6E6-4DC9-AB46-734880D1C631Q43163852-524C1A69-210E-42AA-AA11-897B5DE3A850Q43271832-BF47EE4C-6B4D-4DE8-ABDF-4809B55F0007Q43279860-5978FAF2-642F-4D07-A4AC-900D552ED35EQ43500253-FE5B559E-CFC1-4C0A-9172-0552640D8FC6Q43648271-32C13693-9081-4659-A04F-9EF2237C653FQ43724216-A55FCB41-7759-407D-AD97-51424113B6DAQ44258662-A2B3CE74-18DF-4BC1-9160-B43FBC39FDE8Q45089452-B6D92270-EE85-463E-8138-D293A8684980Q45373378-C0DB9CFA-42FE-4E4B-A17F-4DE48692A231Q45789357-89ABE28B-800F-438D-9CB0-D226A341FC9CQ45925267-566C6127-A640-4441-83BB-F2C329847976Q46060844-44392721-D9E6-4B36-8781-CC1194451B34Q46090522-69E26C8F-D965-432C-ACBB-73309CB65FBEQ46176380-9397C183-042E-4289-84F9-45B3136B1F2CQ46201503-C29A7263-00A9-4B26-9A12-F5ECE18C44C7Q46282162-AFE68750-58FB-4693-9E31-1927DAB3CCFB
P50
description
Polish internist and cardiologist
@en
cairdeolaí Polannach
@ga
cardiólogu polacu
@ast
polnischer Kardiologe
@de
polski lekarz, internista, kardiolog
@pl
name
Paweł Buszman
@ast
Paweł Buszman
@ca
Paweł Buszman
@cs
Paweł Buszman
@en
Paweł Buszman
@es
Paweł Buszman
@fr
Paweł Buszman
@ga
Paweł Buszman
@hr
Paweł Buszman
@hsb
Paweł Buszman
@pl
type
label
Paweł Buszman
@ast
Paweł Buszman
@ca
Paweł Buszman
@cs
Paweł Buszman
@en
Paweł Buszman
@es
Paweł Buszman
@fr
Paweł Buszman
@ga
Paweł Buszman
@hr
Paweł Buszman
@hsb
Paweł Buszman
@pl
altLabel
Pawel E Buszman
@en
Paweł Buszman
@en
Paweł E Buszman
@ast
Paweł E Buszman
@ca
Paweł E Buszman
@en
Paweł E Buszman
@es
Paweł E Buszman
@fr
Paweł E Buszman
@pl
Paweł E Buszman
@sq
Paweł E. Buszman
@pl
prefLabel
Paweł Buszman
@ast
Paweł Buszman
@ca
Paweł Buszman
@cs
Paweł Buszman
@en
Paweł Buszman
@es
Paweł Buszman
@fr
Paweł Buszman
@ga
Paweł Buszman
@hr
Paweł Buszman
@hsb
Paweł Buszman
@pl
P214
P1412
P1559
Paweł Buszman
@pl
P19
P21
P213
0000 0000 7177 5349
P214
P27
P31
P3124
P496
0000-0002-2511-4077
P569
1961-01-23T00:00:00Z
P734
P7859
viaf-101678461